This page shows only what two FDA drug labels say about each other. Each quote below is copied word for word from label text stored by OmniRx; table rows are shown as extracted, so column text can run together.
Fluoxetine label names tramadol
Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (4), Drug Interactions (7.1) ] .
05b0781b-50e2-4311-bde0-430b96e2ef8e, version 4, effective 2024-07-12. Open on DailyMed.Tramadol label names fluoxetine
Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved.
004de5a4-80f8-4040-a6ea-be5e99352a36, version 24, effective 2025-11-20. Open on DailyMed. First part of the label entry titled Inhibitors of CYP2D6.Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome. After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease and the M1 plasma concentration will increase which could increase or prolong therapeutic effects but also increase adverse reactions related to opioid toxicity, and may cause potentially fatal respiratory depression [see Clinical Pharmacology ( 12.3 )] . Intervention: If concomitant use of a CYP2D6 inhibitor is necessary, evaluate patients at frequent intervals for adverse reactions including opioid withdrawal, seizures, and serotonin syndrome. If a CYP2D6 inhibitor is discontinued, consider lowering tramadol hydrochloride extended-release tablets dosage until stable drug effects are achieved. Evaluate patients at frequent intervals for adverse events including respiratory depression and sedation. Examples Quinidine, fluoxetine, paroxetine and bupropion
004de5a4-80f8-4040-a6ea-be5e99352a36, version 24, effective 2025-11-20. Open on DailyMed. Later part of the same entry, which ends with its Examples line. One sentence between the two parts is left out because it contains a character the stored copy of the label has corrupted.Tramadol label names a drug class
FDA's own class record for fluoxetine: Serotonin Uptake Inhibitors [MoA]; Serotonin Reuptake Inhibitor [EPC]. Sources: openFDA label record, NLM RxClass. This product uses publicly available data from the U.S. National Library of Medicine (NLM). Whether the class statement below applies to fluoxetine depends on the label's own wording.
Increased Risk of Seizures : Present within recommended dosage range. Risk is increased with higher than recommended doses and concomitant use of SSRIs, SNRIs, anorectics, tricyclic antidepressants and other tricyclic compounds, other opioids, MAOIs, neuroleptics, other drugs that reduce seizure threshold, in patients with epilepsy or at risk for seizures.
004de5a4-80f8-4040-a6ea-be5e99352a36, version 24, effective 2025-11-20. Open on DailyMed.Cases of serotonin syndrome, a potentially life-threatening condition, have been reported with the use of tramadol products, including tramadol hydrochloride extended-release tablets, particularly during concomitant use with serotonergic drugs. Serotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans
004de5a4-80f8-4040-a6ea-be5e99352a36, version 24, effective 2025-11-20. Open on DailyMed.Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Warnings and Precautions (5.9) ]. Intervention: If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue tramadol hydrochloride extended-release tablets if serotonin syndrome is suspected. Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs)
004de5a4-80f8-4040-a6ea-be5e99352a36, version 24, effective 2025-11-20. Open on DailyMed.Where this comes from
FDA drug label text via openFDA (public domain), US labels only, stored in OmniRx edition 2026-11 (root 98912c55a72b), read on 2026-11-13. A passage here is a record that a label names a drug, not a finding that the two interact. Ask your pharmacist or prescriber about your own medicines, and do not start, stop or change a medicine because of anything on this site.